INSM · Insmed Incorporated
$93.33
-0.06% last session
End-of-day data · close of 2026-10-26
Market cap
$20B
Enterprise value
$20B
Trailing P/E
—
Forward P/E
117.4
Dividend yield
0.0%
Beta
0.82
Avg volume
3M
Employees
2K
Daily Change %
-0.06%
5 Days Change
-1.82%
10 Days Change
-3.05%
30 Days Change
-20.79%
60 Days Change
-21.27%
Month to Day Change
-14.05%
Year to Day Change
-46.37%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — INSM
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-21
Latest call per bank · past 12 months
Morgan Stanley
Overweight$213
+128.2% vs priceBarclays
Overweight$207
+121.8% vs priceJP Morgan
Overweight$175
+87.5% vs priceWells Fargo
Overweight$169
+81.1% vs priceRBC Capital
Outperform$195
+108.9% vs priceBank of America
Buy$213
+128.2% vs priceUBS
Buy$215
+130.4% vs priceGoldman Sachs
Buy$225
+141.1% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-21 | Morgan Stanley | Maintains | Overweight | $218 → $213 |
| 2026-10-12 | Wolfe Research | Downgrade | Outperform → Peer Perform | $0.00 |
| 2026-10-12 | HC Wainwright & Co. | Reiterates | Buy | $0.00 → $220 |
| 2026-09-30 | Barclays | Maintains | Overweight | $237 → $207 |
| 2026-09-15 | Roth Capital | Reiterates | Buy | $212 → $198 |
| 2026-08-10 | JP Morgan | Maintains | Overweight | $179 → $175 |
| 2026-08-10 | Truist Securities | Reiterates | Buy | $185 → $195 |
| 2026-08-07 | Guggenheim | Maintains | Buy | $207 → $205 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-26
- bullish: RSI (14): RSI is 28 — oversold territory; selling pressure looks stretched.
- bearish: Price vs 50-day MA: Trading 18.6% below the 50-day MA ($114.59).
- bearish: Price vs 200-day MA: Trading 26.3% below the 200-day MA ($126.69).
- bearish: MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- bearish: MACD (12,26,9): MACD histogram is negative (-0.12) — short-term momentum is fading.
- bearish: 52-week range: Price is within 10% of the 52-week low ($91.88).
INSM Price Chart
Loading chart for INSM…
Fundamentals
About Insmed Incorporated
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also develops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa. In addition, the company is developing treprostinil palmitil inhalation powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil, which is in phase 3 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; and phase 2 clinical trial for the treatment of pulmonary arterial hypertension. Further, it develops INS1201, a microdystrophin adeno-associated virus gene replacement therapy which is in phase 1 clinical trial for the treatment of Duchenne muscular dystrophy, as well as it is also developing pre-clinical research programs for gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. In addition, it provides INS1148, monoclonal antibody targeting stem cell factor called SCF248 that is in phase-2 clinical trial for the treatment of interstitial lung disease, and asthma; and INS1202, an intrathecally delivered gene therapy which is in phase 1 of clinical trial for the treatment of amyotrophic lateral sclerosis. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$131B 14.1% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$83B 5.0% YTD
MRNA
Moderna, Inc.
$79B 574.3% YTD
ARGX
argenx SE
$55B 3.4% YTD
ONC
BeOne Medicines Ltd.
$42B 22.1% YTD
RVMD
Revolution Medicines, Inc.
$39B 130.9% YTD
RPRX
Royalty Pharma plc
$37B 69.9% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.